Publications & Works

Publication Network
Published journal articles indexed by SCI, SSCI, and AHCI

Effect of Trastuzumab and Lonidamine-Loaded Lipid Nanoparticles (LNP) on HER2+ Breast Cancer

Ozlem Zurnaci F., Ozdatli Kurtulus S., ŞENGEL TÜRK C. T., HASÇİÇEK C., GÜZEL M.
ChemistrySelect , vol.9, no.22, 2024 (SCI-Expanded) identifier

TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice

Surme S., Ergun C., Gul S., Akyel Y. K., Gul Z. M., Ozcan O., et al.
Biochemical Pharmacology , vol.218, 2023 (SCI-Expanded) identifier identifier

Synthesis of Novel Hybrid Lonidamine-Coumarin Derivatives and Their Anticancer Activities

Ipek Ö., Sucu B. O., Gül Ş., Yolaçan Ç., Güzel M.
Journal of Molecular Structure , vol.1281, 2023 (SCI-Expanded) Sustainable Development identifier

Determination of antioxidant, anticancer, antidiabetic and antimicrobial activities of Turkish red pine<i> (Pinus</i><i> brutia</i> Ten.) bark ultrasound-assisted extract as a functional food additive

Erol K., Kutlu G., Tornuk F., Guzel M., Donmez I.
ACTA ALIMENTARIA , vol.52, no.1, pp.102-112, 2023 (SCI-Expanded) identifier

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19

Karatas H., Hanashalshahaby E. H. A., Catal U., Butun Y. E., Kurt E., Gursel S., et al.
Chemical Papers , vol.77, no.3, pp.1695-1702, 2023 (SCI-Expanded) Creative Commons License identifier identifier identifier

Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice

Gul S., Akyel Y. K., Gul Z. M., Isin S., Ozcan O., Korkmaz T., et al.
Nature Communications , vol.13, no.1, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier

Cytotoxic Activity and Docking Studies of 2-arenoxybenzaldehyde N-acyl Hydrazone and 1,3,4-Oxadiazole Derivatives against Various Cancer Cell Lines

Aydın E., Şentürk A. M., BAŞPINAR KÜÇÜK H., GÜZEL M.
Molecules , vol.27, no.21, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier

Mechanistic insight into impact of phosphorylation on the enzymatic steps of farnesyltransferase

PEKEL H., GÜZEL M., ŞENSOY Ö.
Protein Science , vol.31, no.10, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

Lamotrigine derivatives-synthesis, anti-cancer, and anti-MDR-bacterial activities

Khan M. K., Siddiqui H., Sharif R., GÜZEL M., Wahab A., Yousuf S., et al.
Journal of Molecular Structure , vol.1264, 2022 (SCI-Expanded) identifier identifier

An efficient approach to access 2,5-disubstituted 1,3,4-oxadiazoles by oxidation of 2-arenoxybenzaldehyde N-acyl hydrazones with molecular iodine

BAŞPINAR KÜÇÜK H., Alhonaish A., YILDIZ T., GÜZEL M.
ChemistrySelect , vol.7, no.26, 2022 (SCI-Expanded) identifier identifier

Design and synthesis of novel caffeic acid phenethyl ester (CAPE) derivatives and their biological activity studies in glioblastoma multiforme (GBM) cancer cell lines

SUCU B. O., Koc E. B., Savlug Ipek Ö., Mirat A., Almas F., Guzel M. A., et al.
Journal of Molecular Graphics and Modelling , vol.113, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

Potential of Novel Methyl Jasmonate Analogs as Anticancer Agents to Metabolically Target HK-2 Activity in Glioblastoma Cells

Uludağ D., Bay S., SUCU B. O., Şavluğ İpek Ö., Mohr T., GÜZEL M., et al.
Frontiers in Pharmacology , vol.13, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

Instant determination of the artemisinin from various Artemisia annua L. extracts by LC-ESI-MS/MS and their in-silico modelling and in vitro antiviral activity studies against SARS-CoV-2

DOĞAN K. M., EROL E., Didem Orhan M., Degirmenci Z., Kan T., Gungor A., et al.
Phytochemical Analysis , vol.33, no.2, pp.303-319, 2022 (SCI-Expanded) identifier identifier identifier

Novel β‑hydroxy ketones: Synthesis, spectroscopic characterization, molecular docking, and anticancer activity studies

BAŞPINAR KÜÇÜK H., Kanturk G., YERLİKAYA Ş., YILDIZ T., Senturk A. M., GÜZEL M.
Journal of Molecular Structure , vol.1250, 2022 (SCI-Expanded) identifier identifier

The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

Durdagi S., Avsar T., Orhan M. D., Serhatli M., Balcioglu B. K., Ozturk H. U., et al.
Molecular Therapy , vol.30, no.2, pp.963-974, 2022 (SCI-Expanded) identifier identifier identifier

Welcome message

YİĞİTBAŞI T., GÜZEL M.
Turkish Journal of Biochemistry , vol.46, no.S1, pp.4, 2021 (SCI-Expanded) Creative Commons License identifier

Design and synthesis of novel cylopentapyrazoles bearing 1,2,3-thiadiazole moiety as potent antifungal agents

Giray B., KARADAĞ A. E., İpek Ö., PEKEL H., GÜZEL M., BAŞPINAR KÜÇÜK H.
Bioorganic Chemistry , vol.95, 2020 (SCI-Expanded) identifier identifier identifier

Novel synthetic approaches for bisnaphthalimidopropyl (BNIP) derivatives as potential anti-parasitic agents for the treatment of leishmaniasis

Keskin E., Ucisik M. H., SUCU B. O., GÜZEL M.
Molecules , vol.24, no.24, 2019 (SCI-Expanded) Creative Commons License Sustainable Development identifier identifier identifier

Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model

Piranlioglu R., Lee E., Ouzounova M., Bollag R. J., Vinyard A. H., Arbab A. S., et al.
Nature Communications , vol.10, no.1, 2019 (SCI-Expanded) Creative Commons License Sustainable Development identifier identifier identifier

Synthesis of novel methyl jasmonate derivatives and evaluation of their biological activity in various cancer cell lines

SUCU B. O., Ipek Ö., Kurtulus S. O., Yazici B. E., KARAKAŞ N., GÜZEL M.
Bioorganic Chemistry , vol.91, 2019 (SCI-Expanded) Sustainable Development identifier identifier identifier

The pleiotropic effects of TNFα in breast cancer subtypes is regulated by TNFAIP3/A20

Lee E., Ouzounova M., Piranlioglu R., Ma M. T., GÜZEL M., Marasco D., et al.
Oncogene , vol.38, no.4, pp.469-482, 2019 (SCI-Expanded) Creative Commons License Sustainable Development identifier identifier identifier

Synthesis of substituted pyridines from 1,2-nucleophilic addition products of functionalized N-acyl-2,3-dihydropyridones

GÜZEL M., Watts J., Mcgilvary M., Wright M., Kiren S.
Tetrahedron Letters , vol.56, no.38, pp.5275-5277, 2015 (SCI-Expanded) identifier identifier

Stereoselective route to mitosanes via tricarbonyl eta(6) arene chromium complexes

GÜZEL M.
TETRAHEDRON LETTERS , vol.41, no.8, pp.0-1126, 2000 (SCI-Expanded) identifier
Articles Published in Other Journals

Antileishmanial Activity of BNIPDaoct- and BNIPDanon-loaded Emulsomes on Leishmania infantum Parasites

Islek Z., Ucisik M. H., Keskin E., SUCU B. O., Gomes‐Alves A. G., Tomás A. M., et al.
Frontiers in Nanotechnology , vol.3, 2022 (Scopus) Creative Commons License identifier

Essential parameters and risk factors of the patients for diabetes care and treatment

Bener A., Keskin F. E., KURTULUŞ E. M., GÜZEL M., Çekirdekçi E. I., KADIOĞLU P., et al.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews , vol.11, 2017 (Scopus) identifier identifier identifier

Gender Satisfaction among Type 2 Diabetes Patients: A Comparison between Intensive Diets, Lifestyle Intervention with Medication Controlled Management

BENER A., Al HAMAQ A. O., ÇATAN F., RAJPUT K. U., GÜZEL M.
British Journal of Medicine Medical Research , vol.18, no.7, pp.1-13, 2016 (Peer-Reviewed Journal) identifier
Papers Published in Refereed Scientific Meetings

SYNTHESIS OF NEW DUAL DRUG CANDIDATES THAT MAY HAVE THERAPEUTIC EFFECT AND DETERMINATION OF THEIR BIOLOGICAL ACTIVITIES

Şavluğ İpek Ö., SUCU B. O., GÜZEL M., YOLAÇAN Ç.
10th International Drug Chemistry Congress, Antalya, Turkey, 10 - 12 March 2022

Tripalmitin-based Emulsome Formulations for Sustained Delivery of Antileishmanial Compounds to Infected Macrophages

İŞLEK Z., SUCU B. O., KESKİN E., GÜZEL M., ŞAHİN F., ÜÇIŞIK M. H.
7th International BAU Drug Design Congress, İstanbul, Turkey, 19 - 21 December 2019, pp.75

Glioblastoma Multiform Hücre Hatlarında Özgün Kafeik Asit Fenetil Ester Analoglarının Anti-Kanser Etkisinin Araştırılması

SUCU B. O., Koç E. B., KARAKAŞ N., GÜZEL M.
7.International Drug Chemistry Conference, Antalya, Turkey, 14 March 2019

Therapeutic Effects of Novel Methyl Jasmonate Derivatives on Brain Cancer Cell Lines

Uludağ D., SUCU B. O., Şavluğ Ö., Yazıcı E., GÜZEL M., KARAKAŞ N.
3rd Annual Meeting MuTaLig COST Action, Malta, Italy, 18 October 2018

Targeting different types of cancers by Novel Methyl Jasmonate Derivatives

YAZICI E., SUCU B. O., Şavluğ Ö., Uludağ D., KARAKAŞ N., GÜZEL M.
3rd Annual Meeting MuTaLig COST Action, Malta, Italy, 18 October 2018

Anti-cancer Effects of Novel Caffeic Acid Phenthyl Ester (CAPE) Analogues on Glioblastome Multiforme Cell Lines

Tosyalı İ. S., Öztür İ., Koç E. B., Güzel M. A., SUCU B. O., Şavluğ Ö., et al.
7. Multidisipliner Kanser Araştırma ve 1.Temel Onkoloji Kongresi (MOKAD 2018), İzmir, Turkey, 11 October 2018

Solid Lipid Emulsions for Delivery of Water-Insoluble Drug Candidates against Leishmaniasis

ÜÇIŞIK M. H., İŞLEK KÖKLÜ Z., Keskin E., SUCU B. O., GÜZEL M., ŞAHİN F.
CLINAM 2018: European Submit for Clinical Nanomedicine, Bazel, Switzerland, 2 - 05 September 2018

Emulsome-based targeted delivery of anti-leishmanial compounds to macrophages

İŞLEK Z., SUCU B. O., KESKİN E., GÜZEL M., ŞAHİN F., ÜÇIŞIK M. H.
11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine – The Building Blocks to Personalized Medicine, Basel, Switzerland, 2 - 05 September 2018, pp.232-234

Novel Drug Discovery Approaches for Cancer with the Inspiration of a Natural Product - Methyl Jasmonate

SUCU B. O., Şavluğ Ö., ÖZDATLI Ş., GÜZEL M.
25th Biennial Congress of the European Association for Cancer Research (EACR25), Amsterdam, Netherlands, 30 June - 03 July 2018 Sustainable Development

Prostat Kanserini Tedavi Etmek İçin Dosetaksel Konjuge, Prostat Spesifik Membran Antijen Hedefli Aptamer Komplekslerinin Geliştirilmesi

SUCU B. O., Hussein W., GÜZEL M.
Uluslararası Katılımlı 6. İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi ve Standardizasyonu Kongresi, Antalya, Turkey, 22 - 25 March 2018 Sustainable Development

Hekzokinaz-2 Enzim İnhibitörü Özgün Metil Jasmonat Analoglarının Sentezi ve İn-Vitro Çalışmaları

SUCU B. O., Şavluğ Ö., ÖZDATLI Ş., GÜZEL M.
Uluslararası Katılımlı 6. İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi ve Standardizasyonu Kongresi, Antalya, Turkey, 22 - 25 March 2018

Lipid-Based Emulsome Nanoformulations for Targeted Delivery of Antiparasites

ÜÇIŞIK M. H., İŞLEK KÖKLÜ Z., SUCU B. O., GÜZEL M., ŞAHİN F.
IV Symposium of Tropical Health / COST Action CM 1307 (WG3 and WG4) Joint Meeting, Pamplona, Spain, 4 - 05 May 2017, pp.1-82

Hekzokinaz-2 Enzim İnhibitörü Olarak Kullanılabilecek Anti-Kanser Ajanı Özgün Metil Jasmonat Analoglarının Sentezi ve İn-Vitro Çalışmaları

şavluğ ö., SUCU B. O., YOZGAT Y., GÜZEL M.
5. İLAÇ KİMYASI: İLAÇ ETKİN MADDESİ TASARIMI, SENTEZİ, ÜRETİMİ VE STANDARDİZASYONU KONGRESİ, Turkey, 30 March - 02 April 2017 Sustainable Development

Özgün Anti-Kanser İlaç Adayı Keşif ve GeliştirmeÇalışmaları

SUCU B. O., GÜZEL M.
III. Ulusal Organik Kimya Kongresi, Turkey, 5 - 08 September 2016 Sustainable Development

Leishmaniasis’in Tedavisine Yönelik Özgün İlaç Moleküllerinin Keşfi ve Geliştirme Çalışmaları

gölcük a., SUCU B. O., GÜZEL M., ÜÇIŞIK M. H.
III. Ulusal Organik Kimya Kongresi, Turkey, 5 - 08 September 2016

Synthesis and Biological Evaluation of New A2a Adenosine Receptor Antagonists for the Treatment of Parkinson s Disease

ÖZDATLI Ş., SUCU BAVKIR B. O., Hanife P., GÜZEL M.
International Multidisciplinary Symposium on Drug Research and Development, 15 - 18 October 2015, vol.1, pp.176

Beyond Warburg Effect Treatment of Cancer as a Metabolic Disease

GÜZEL M.
İnternational BAU Drug Design Congress, İstanbul, Turkey, 1 - 03 October 2015

Novel Targets for Cancer Metabolism

GÜZEL M.
Design of Synthetic Chemical Probes: Tools and Strategies in Medicine &Chemical Biology, İstanbul, Turkey, 13 - 15 September 2015

Novel Drug Candidates for Type 2 Diabetes Mellitus T2DM

GÜZEL M.
Drug Discovery & Therapy World Congress, BOSTON, United States Of America, 22 - 25 July 2015

Novel Metabolic Targets For Cancer Therapy

GÜZEL M.
International 3rd Anticancer Agent Development Congress, İzmir, Turkey, 18 - 19 May 2015

Parkinson Hastalığı Tedavisi İçin Yeni A2A Adenosin Reseptör Antagonistlerinin Sentezi Ve Aktivitelerinin Değerlendirilmesi

ÖZDATLI Ş., SUCU B. O., GÜZEL M.
3.İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi ve Standardizasyonu Kongresi, Turkey, 20 - 22 March 2015

Novel GLP 1R Agonists Road to a Benchmark Drug

GÜZEL M.
National Medicinal Chemistry Congress, Antalya, Turkey, 20 - 22 March 2015

Synthesis of Novel A2A Adenosine Receptor Antagonists Evaluation and SAR of New Molecules

ÖZDATLI Ş., SUCU BAVKIR B. O., GÜZEL M.
National Medicinal Chemistry Congress, Antalya, Turkey, 20 - 22 March 2015

Novel Glucokinase Activators Road to a Benchmark Drug

GÜZEL M.
International Anatolian Conference on Synthetic Organic Chemistry, Antalya, Turkey, 16 - 19 March 2015

Türkiye de İlaç İstismarı Bonzai İle Ölüme Giden Yol Davetli Yazar

GÜZEL M.
Sağlık Düşüncesi ve Tıp Kültürü Dergisi, Turkey, 14 December 2014, pp.58-61

Medisinal Kimyanın Yenilikçi İlaç Keşif ve Geliştirmedeki Rolü ve Önemi

GÜZEL M.
İlaç ve Eczacılık Kongresi, 28 - 30 November 2014

The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis

GÜZEL M.
2014 Joint ACTRIMS-ECTRIMS Meeting, BOSTON, United States Of America, 9 September - 09 October 2014

Türkiye de Yenilikçi İlaç İçin Yol Haritası Davetli Yazar

GÜZEL M.
Sağlık Düşüncesi ve Tıp Kültürü Dergisi, Turkey, 15 June 2014, pp.51-57

Glucokinase Activators Road to a Benchmark Drug

GÜZEL M.
International BAU Drug Design Congress, İstanbul, Turkey, 17 - 19 April 2014

Novel Bach 1 modulators increase heme oxygenase 1 HMOX 1 and suppress elevation of blood pressure in the Goldblatt model of renovascular hypertension

GÜZEL M.
American Heart Association HBPR symposium, Washington, Kiribati, 5 - 08 September 2013

Liver Selective Glucokinase Activators A New Treatment Paradigm for Diabetic Patients

GÜZEL M.
Pharmaceutical Developments, BOSTON, United States Of America, 01 November 2009

TTP355 a Liver Selective Glucokinase Activator

GÜZEL M.
American Diabetes Association, New York, United States Of America, 1 - 03 June 2008

Dual Point Binding Enantioselective Catalysts

GÜZEL M.
National Organic Symposium, United States Of America, 13 June 1999

Asymmetric Catalysis via Arene Chromium 0 Carbonyl Complexes

GÜZEL M.
ACS 216th National Meeting, BOSTON, United States Of America, 23 August 1998

Dual Point Binding Enantioselective Lewis Acid Catalysts

GÜZEL M.
National Organic Symposium, United States Of America, 22 June 1997